The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effects of Ganopoly®(A Ganoderma lucidum Polysaccharide Extract) on the Immune Functions in Advanced‐Stage Cancer Patients
Abstract
Preclinical studies have established that the Ganoderma lucidum polysaccharide (GLPS) fractions have potent anti-tumor activity, which has been associated with the immuno-stimulating effects of GLPS. However, it is unclear whether GLPS has immuno-modulating effects in humans in vivo. This study aimed to investigate the effects of Ganopoly, the polysaccharides fractions extracted from G. lucidum, on the immune function of advanced-stage cancer patients. Thirty-four advance-stage cancer patients were entered onto this study, and treated with 1800 mg Ganopoly, three times daily orally before meals for 12 weeks. Immune parameters (cytokines, T cell subsets, mitotic response to phytohemagglutinin (PHA) and natural killer activity) were compared between baseline and after 12-week treatment. Thirty patients are assessable for their immune functions. Treatment of Ganopoly for 12 weeks resulted in a significant (P < 0.05) increase in the mean plasma concentrations of interleukin (IL-2), IL-6, and interferon (IFN)-gamma, whereas the levels of IL-1 and tumor necrosis factor (TNF-alpha) were significantly (P < 0.05) decreased. A marked variability among patients with advanced-stage cancer was observed in the numbers of each lymphocyte subset at baseline. The mean absolute number of CD56+ cells was significantly (P < 0.05) increased after 12-week treatment of Ganopoly, whereas the numbers of CD3+, CD4+, and CD8+ were just marginally increased compared to baseline levels, with the CD4:CD8 T cell ratios unchanged. PHA responses after 12-week treatment with Ganopoly were enhanced in most patients, when compared to pretreatment baselines (P < 0.05). In addition, Ganopoly treatment resulted in a significant increase (P < 0.05) in the mean NK activity compared to baselines (34.5 +/- 11.8% vs 26.6 +/- 8.3%). The present study indicates that Ganopoly enhanced the immune responses in patients with advanced-stage cancer. Clinical evaluations of response and toxicity are ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
The principles and practice of oncology
Johnston, P. G., & McDermott, U. (2001) · Oncology · doi:10.1093/oso/9780192629821.003.0001 · Cited by 961
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Crystal structure of the A domain from the a subunit of integrin CR3 (CD11 b/CD18)
Lee, J.-O., Rieu, P., Arnaout, M. A., & Liddington, R. (1995) · Cell · doi:10.1016/0092-8674(95)90517-0 · Cited by 887
Therapeutic Effects of Substances Occurring in Higher Basidiomycetes Mushrooms: A Modern Perspective
Weis, A. L., & Wasser, S. P. (1999) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v19.i1.30 · Cited by 770
Mechanism-Based Target Identification and Drug Discovery in Cancer Research
Gibbs, J. B. (2000) · Science · doi:10.1126/science.287.5460.1969 · Cited by 606
Thornton, B. P., Vĕtvicka, V, Pitman, M., Goldman, R. C., & Ross, G. D. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.3.1235 · Cited by 589
Diamond, M. S., Garcia-Aguilar, J., Bickford, J. K., Corbi, A. L., & Springer, T. A. (1993) · The Journal of cell biology · doi:10.1083/jcb.120.4.1031 · Cited by 533
Villegas, F. R., Coca, S., Villarrubia, V. G., Jiménez, R., Chillón, M. J., Jareño, J., Zuil, M., & Callol, L. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00292-6 · Cited by 467
Wang, S.-Y., Hsu, M.-L., Hsu, H.-C., Lee, S.-S., Shiao, M.-S., & Ho, C.-K. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970317)70:6<699::aid-ijc12>3.0.co;2-5 · Cited by 455
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343 · cited 2×
“Evidence has indicated that the immune function can be reduced or damaged in cancer patients receiving chemotherapy and radiotherapy, resulting in an decrease in cytotoxic T lymphocyte and NK activity (Kempf and Mitchell, 1985; Santin et al., 2000; Tsavaris et al., 2002).”
BackgroundMethodImmunological Surveillance in Neoplasia
Burnet, F. M. (1971) · Immunological Reviews · doi:10.1111/j.1600-065x.1971.tb00461.x · Cited by 342
Natural killer cells and cancer
Brittenden, J., Heys, S. D., Ross, J., & Eremin, O. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1226::aid-cncr2>3.0.co;2-g · Cited by 319
Mueller, A., Raptis, J., Rice, P. J., Kalbfleisch, J. H., Stout, R. D., Ensley, H. E., Browder, W., & Williams, D. L. (2000) · Glycobiology · doi:10.1093/glycob/10.4.339 · Cited by 302
Human natural killer cells: their origin, receptors and function
Moretta, L., Bottino, C., Pende, D., Mingari, M. C., Biassoni, R., & Moretta, A. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200205)32:5<1205::aid-immu1205>3.0.co;2-y · Cited by 266
The role of cytokines in cancer cachexia
Argilés, J. M. A., & López-Soriano, F. J. (1999) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199905)19:3<223::aid-med3>3.0.co;2-n · Cited by 234
MIYAZAKI, T., & NISHIJIMA, M. (1981) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.29.3611 · Cited by 204
Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer
Small, E. J., Frohlich, M. W., Bok, R., Shinohara, K., Grossfeld, G., Rozenblat, Z., Kelly, W. K., Corry, M., & Reese, D. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3595 · Cited by 182
Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum
Liu, X. B., Yuan, J., Chung, C.-K., & Chen, X.-J. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00080-0 · Cited by 158
Müller, A., Rice, P. J., Ensley, H. E., Coogan, P. S., Kalbfleisch, J. H., Kelley, J., Love, E. J., Portera, C. A., Ha, T., Browder, I. W., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3418 · Cited by 134
Plant polysaccharides with immunostimulatory activities
Paulsen, B. (2001) · Current Organic Chemistry · doi:10.2174/1385272013374987 · Cited by 133
Müller, A., Rice, P. J., Ensley, H. E., et al. (1996) · PubMed · Cited by 128
Recent advances: Complementary medicine
Vickers, A. J. (2000) · BMJ · doi:10.1136/bmj.321.7262.683 · Cited by 113
Goto, S., Sato, M., Kaneko, R., Itoh, M., Sato, S., & Takeuchi, S. (1999) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050620 · Cited by 105
Santin, A. D., Hermonat, P. L., Ravaggi, A., Bellone, S., Roman, J. J., Pecorelli, S. L., Cannon, M. J., & Parham, G. P. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00769-0 · Cited by 102
Battle, J., Ha, T., Li, C., Beffa, V. D., Rice, P. J., Kalbfleisch, J. H., Browder, W., & Williams, D. L. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9175 · Cited by 98
Immunostimulating Agents: What Next?
Werner, G. H., & Jollès, P. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0001r.x · Cited by 77
Usui, T., Iwasaki, Y., Mizuno, T., Tanaka, M., Shinkai, K., & Arakawa, M. (1983) · Carbohydrate Research · doi:10.1016/0008-6215(83)88159-2 · Cited by 57
5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA): a New Biological Response Modifier for Cancer Therapy
Zhou, S., Kestell, P., Baguley, B. C., & Paxton, J. W. (2002) · Investigational New Drugs · doi:10.1023/a:1016215015530 · Cited by 50
Self-citationPHARMACOLOGY OF CANCER CHEMOTHERAPY
Greenwald, E. S. (1967) · Elsevier eBooks · doi:10.1016/b978-1-4832-1346-0.50007-3 · Cited by 46
Jović, V., Konjević, G. M., Radulovic, S. S., Jelić, S., & Spužić, I. (2001) · Tumori Journal · doi:10.1177/030089160108700509 · Cited by 45
Effects of Chemotherapeutic Agents on the Immune Response. II
Kempf, R. A., & Mitchell, M. S. (1985) · Cancer Investigation · doi:10.3109/07357908509040605 · Cited by 44
Cited by
Impact of plant products on innate and adaptive immune system of cultured finfish and shellfish
Harikrishnan, R., Balasundaram, C., & Heo, M.-S. (2011) · Aquaculture · doi:10.1016/j.aquaculture.2011.03.039 · Cited by 650
Nutritional predictors of postoperative outcome in pancreatic cancer
Kanda, M., Fujii, T., Kodera, Y., Nagai, S., Takeda, S., & Nakao, A. (2011) · Journal of British Surgery · doi:10.1002/bjs.7305 · Cited by 609
Ganoderma lucidum and its pharmaceutically active compounds
Boh, B., Berovic, M., Zhang, J., & Zhi-Bin, L. (2007) · Biotechnology Annual Review · doi:10.1016/s1387-2656(07)13010-6 · Cited by 594
Meng, X., Liang, H., & Luo, L. (2016) · Carbohydrate Research · doi:10.1016/j.carres.2016.02.008 · Cited by 482
Shao, B.-M., Xu, W., Dai, H., Tu, P., Li, Z., & Gao, X.-M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.06.065 · Cited by 395
Metadata
- Authors
- Gao, Y., Zhou, S., Jiang, W., Huang, M., & Dai, X.
- Venue
- Immunological Investigations
- Publisher
- Informa UK Limited
- Published
- 2003-01
- Volume
- 32
- Issue
- 3
- Pages
- 201-215
- ISSN
- 0882-0139 (ISSN-L)
- 1532-4311
- OpenAlex
- W2037909222
- Cited by
- 283
- References
- 32
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.